<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00419328</url>
  </required_header>
  <id_info>
    <org_study_id>NGR002</org_study_id>
    <secondary_id>2004-002194-23</secondary_id>
    <nct_id>NCT00419328</nct_id>
  </id_info>
  <brief_title>A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors</brief_title>
  <official_title>NGR002: A Modified Phase I Study of NGR-hTNF in Advanced Solid Tumors: Definition of an Optimal Biological Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGC Biologics S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AGC Biologics S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the trial is to explore the safety and biological activity of NGR-hTNF.&#xD;
      The safety will be established by clinical and laboratory assessment. The biological activity&#xD;
      will be evaluated by DCE-MRI with contrast media.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a modified phase I Single arm, open, non randomized trial of NGR-hTNF in advanced&#xD;
      solid tumors for the definition of an optimal biological&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To verify safety of escalating doses of NGR-hTNF</measure>
    <time_frame>during and following the treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To document possible modifications on vessels permeability</measure>
    <time_frame>before and following the first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To document signs of anticancer activity</measure>
    <time_frame>every 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NGR-hTNF</intervention_name>
    <description>iv q3W escalating dose up 1.6 mcg/sqm</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients &gt;18 years old with proven advanced solid tumors not amenable to any clinical&#xD;
             improvement by current standard treatments. Tumors recognized to be highly&#xD;
             vascularized (e.g. renal, colon thyroid and head and neck cancers), will be included.&#xD;
&#xD;
          -  ECOG Performance status 0 - 2&#xD;
&#xD;
          -  Patients may have had prior therapy providing the following conditions are met:&#xD;
&#xD;
               -  Chemo, radio, hormonal or immunotherapy: wash-out period of 28 days&#xD;
&#xD;
               -  Surgery: wash-out period of 14 days&#xD;
&#xD;
          -  Adequate baseline bone marrow, hepatic and renal function, defined as follows:&#xD;
&#xD;
          -  Neutrophils &gt; 1.5 x 10^9/L and platelets &gt; 100 x 10^9/L&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 x ULN&#xD;
&#xD;
          -  AST and/or ALT &lt; 2.5 x ULN in absence of liver metastases&#xD;
&#xD;
          -  AST and/or ALT &lt; 5 x ULN in presence of liver metastases&#xD;
&#xD;
          -  Serum creatinine &lt; 1.5 x ULN&#xD;
&#xD;
          -  Absence of any conditions in which hypervolemia and its consequences (e.g. increased&#xD;
             stroke volume, elevated blood pressure) or haemodilution could represent a risk for&#xD;
             the patient (reference appendix &quot;Technical data sheet human albumin&quot;)&#xD;
&#xD;
          -  Normal cardiac function and absence of uncontrolled hypertension&#xD;
&#xD;
          -  Patients must give written informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent anticancer therapy&#xD;
&#xD;
          -  Patients may not receive any other investigational agents while on study&#xD;
&#xD;
          -  Clinical signs of CNS involvement&#xD;
&#xD;
          -  Patients with active or uncontrolled systemic disease/infections or with serious&#xD;
             illness or medical conditions, which is incompatible with the protocol&#xD;
&#xD;
          -  Known hypersensitivity/allergic reaction to human albumin preparations or to any of&#xD;
             the excipients&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol&#xD;
&#xD;
          -  Pregnancy or lactation. Patients - both males and females - with reproductive&#xD;
             potential (i.e. menopausal for less than 1-year and not surgically sterilized) must&#xD;
             practice effective contraceptive measures throughout the study. Women of childbearing&#xD;
             potential must provide a negative pregnancy test (serum or urine) within 14 days prior&#xD;
             to registration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Lambiase, MD</last_name>
    <role>Study Director</role>
    <affiliation>AGC Biologics S.p.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondazione San Raffaele del Monte Tabor</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Gregorc V, Citterio G, Vitali G, Spreafico A, Scifo P, Borri A, Donadoni G, Rossoni G, Corti A, Caligaris-Cappio F, Del Maschio A, Esposito A, De Cobelli F, Dell'Acqua F, Troysi A, Bruzzi P, Lambiase A, Bordignon C. Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. Eur J Cancer. 2010 Jan;46(1):198-206. doi: 10.1016/j.ejca.2009.10.005.</citation>
    <PMID>19900802</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>January 5, 2007</study_first_submitted>
  <study_first_submitted_qc>January 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2007</study_first_posted>
  <last_update_submitted>January 28, 2013</last_update_submitted>
  <last_update_submitted_qc>January 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2013</last_update_posted>
  <responsible_party>
    <name_title>MolMed</name_title>
    <organization>MolMed</organization>
  </responsible_party>
  <keyword>solid tumors NGR-hTNF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

